2024-10-20 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Analysis Report

**Company Overview:**  Vertex Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing therapies for severe genetic diseases, primarily cystic fibrosis.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return (VRTX):** 180.04%
* **Cumulative Return (VOO):** 137.88%
* **Relative Divergence:** 42.16% (This means VRTX has outperformed the S&P 500 by 42.16% over the considered period.)
* **Relative Divergence Rank:** 75.75% (This indicates VRTX's performance has been in the top 75.75% percentile compared to its historical performance against the S&P 500.)

**2. Recent Price Trends:**

* **Closing Price:** $483.00
* **5-day Moving Average:** $487.62
* **20-day Moving Average:** $469.43
* **60-day Moving Average:** $476.84

**3. Technical Indicators:**

* **RSI:** 59.31 (Indicates neutral momentum, neither overbought nor oversold)
* **PPO:** 0.76 (Positive value suggests potential for price increases)
* **Delta_Previous_Relative_Divergence:** 2.4 (Positive value suggests short-term upward momentum)
* **Expected Return:** 5.85% (Potential for outperformance compared to the S&P 500 over the long term, 2 years or more, with consistent investment)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | Expected EPS |
|---|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ | N/A |
| 2024-05-07 | 4.26 | 2.69 B$ | N/A |
| 2023-11-07 | 4.01 | 2.48 B$ | N/A |
| 2023-08-02 | 3.55 | 2.49 B$ | N/A |
| 2024-08-02 | 3.55 | 2.49 B$ | N/A |

* **Most Recent Earnings:** The latest earnings report (2024-08-02) shows a significant decline in EPS compared to previous quarters. However, revenue remains consistent, indicating potential for growth in the future.
* **Expected Earnings:** Due to the lack of available data, it's difficult to assess the expected earnings for future quarters.

**5. News and Recent Developments:**

* **Market Outlook:** Despite the recent decline in EPS, analysts remain optimistic about VRTX's long-term prospects, citing its strong market position in the cystic fibrosis treatment space and ongoing research into new therapies.
* **Analyst Opinions:**  According to FINBOLD, the majority of analysts rate VRTX as a "buy" or "strong buy," with a 12-month price target of $540.
* **Performance Highlights:**  VRTX's recent acquisition of private company,  "Longevity Biotech," further solidifies its commitment to expanding its treatment portfolio to include new diseases like amyloidosis and heart failure.

**6. Overall Analysis:**

* Vertex Pharmaceuticals Inc. (VRTX) has consistently outperformed the S&P 500 (VOO) over the considered period. 
* Technical indicators suggest potential for upward price movement, with a neutral RSI and positive PPO and Delta_Previous_Relative_Divergence.
* Despite a recent dip in EPS, VRTX remains a strong company with promising future prospects. 
* Analyst sentiment remains positive, indicating confidence in VRTX's growth potential.

**7. Conclusion:**

VRTX is a promising investment option for investors seeking long-term growth potential in the biotechnology sector. The company's dominance in cystic fibrosis treatment, ongoing research into new therapies, and positive analyst sentiment create a solid foundation for future success. 
